pH sensitive liposomes delivering tariquidar and doxorubicin to overcome multidrug resistance of resistant ovarian cancer cells

Xia, Yuqiong; Mei, Fang; Dong, Jingyu; Xu, Chunzhong; Liao, Zhen; Ning, Pengbo; Zeng, Qi

doi:10.1016/j.colsurfb.2018.06.055

Cited by 32 publications

(13 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of therapeutics, including paclitaxel (PTX) [105,106], doxorubicin (DOX) [107,108], methotrexate [109,110], cis-platin [111,112], curcumin [113,114], 5-fluorouracil [115,116], irinotecan [117,118], and nucleic acids [119,120], have been delivered via polymeric carriers [121] to cells. However, liposomes provide unique properties, as their charge, size, and surface properties can easily be tuned by selecting different ingredients of lipid mixture prior to the preparation of the liposomes.…”

Section: Biomedical Applications Of Folate-conjugated Liposomesmentioning

confidence: 99%

Formulation Strategies for Folate-Targeted Liposomes and Their Biomedical Applications

2019

View full text Add to dashboard Cite

The folate receptor (FR) is a tumor-associated antigen that can bind with folic acid (FA) and its conjugates with high affinity and ingests the bound molecules inside the cell via the endocytic mechanism. A wide variety of payloads can be delivered to FR-overexpressed cells using folate as the ligand, ranging from small drug molecules to large DNA-containing macromolecules. A broad range of folate attached liposomes have been proven to be highly effective as the targeted delivery system. For the rational design of folate-targeted liposomes, an intense conceptual understanding combining chemical and biomedical points of view is necessary because of the interdisciplinary nature of the field. The fabrication of the folate-conjugated liposomes basically involves the attachment of FA with phospholipids, cholesterol or peptides before liposomal formulation. The present review aims to provide detailed information about the design and fabrication of folate-conjugated liposomes using FA attached uncleavable/cleavable phospholipids, cholesterol or peptides. Advances in the area of folate-targeted liposomes and their biomedical applications have also been discussed.

show abstract

Section: Biomedical Applications Of Folate-conjugated Liposomesmentioning

confidence: 99%

Formulation Strategies for Folate-Targeted Liposomes and Their Biomedical Applications

2019

View full text Add to dashboard Cite

show abstract

“…However, chemical drugs often cause damage to normal cells while killing the cancer cells [21]. Meanwhile, tumors can develop multidrug resistance to chemotherapeutic drugs through a variety of mechanisms [22]. Therefore, it is urgent to find a new way to treat colon cancer.…”

Section: Discussionmentioning

confidence: 99%

Fusion protein tTF-EG3287 induces occlusion of tumor vessels and impairs tumor growth in human colon cancer

Qiu¹,

Xie²,

Zhao³

et al. 2019

neo

View full text Add to dashboard Cite

The problems including narrow indications, low drug loading, and difficulty in intervention severely affect the clinical efficacy of anti-tumor embolization. Here, we designed a novel tTF-EG3287 protein consisting of the truncated tissue factor (tTF) fused with the bicyclic polypeptide which was encoded by exons 7 and 8 for accurate localization in the tumor vascular endothelial cells (EG3287). This study aims to explore its anti-cancer effect. Gene sequencing was used to verify the fusion gene and SDS-PAGE gel to confirm the optimal induction time and concentration of tTF-EG3287. Nickel affinity chromatography column was used to purify the fusion protein. Confocal microscopy was used to assess the target activity of tTF-EG3287 on colon cancer cells in vitro. Thrombelastography assay was used to identify the pro-coagulant activity of tTF-EG3287. In in vivo experiments, the specific localization of tTF-EG3287 in tumor tissues and the effect of tTF-EG3287 on tumor thrombosis were further detected by in vivo imaging and HE staining, respectively. The tTF-EG3287 fusion protein was efficiently purified by nickel-affinity chromatography column. Moreover, tTF-EG3287 fusion protein showed strong coagulation a ctivity and specific binding ability to the cell surface of colon cancer. In vivo, tTF-EG3287 stably and persistently accumulated in tumor tissues, and specifically induced mixed thrombus formation in tumor vessels, and then impaired tumor growth (tumor inhibition rate=79.2%, p<0.01). Our data prove that the fusion protein tTF-EG3287 could be used as a novel and promising anti-cancer strategy and has great potential value for clinical applications.

show abstract

“…Xia et al, constructed a pH sensitive liposome formulation by loading tariquidar (TQR) and doxorubicin to overcome multidrug resistance of drug-resistant ovarian cancer cells. The tariquidar and doxorubicin-loaded pH sensitive liposome formulation exhibited outstanding tumour inhibition against the tested cells by increasing the accumulation of doxorubicin in cells, allowing them to enter specifically into the nuclei [241]. Additionally, a newer generation of liposomes are emerging, focusing on redox sensitive liposomes, magnetic liposomes, enzyme sensitive liposomes and multifunctional smart liposomes [242–245].…”

Section: Nanomaterials As Drug Delivery Agentsmentioning

confidence: 99%

Current trends and challenges in cancer management and therapy using designer nanomaterials

Navya¹,

et al. 2019

View full text Add to dashboard Cite

Nanotechnology has the potential to circumvent several drawbacks of conventional therapeutic formulations. In fact, significant strides have been made towards the application of engineered nanomaterials for the treatment of cancer with high specificity, sensitivity and efficacy. Tailor-made nanomaterials functionalized with specific ligands can target cancer cells in a predictable manner and deliver encapsulated payloads effectively. Moreover, nanomaterials can also be designed for increased drug loading, improved half-life in the body, controlled release, and selective distribution by modifying their composition, size, morphology, and surface chemistry. To date, polymeric nanomaterials, metallic nanoparticles, carbon-based materials, liposomes, and dendrimers have been developed as smart drug delivery systems for cancer treatment, demonstrating enhanced pharmacokinetic and pharmacodynamic profiles over conventional formulations due to their nanoscale size and unique physicochemical characteristics. The data present in the literature suggest that nanotechnology will provide next-generation platforms for cancer management and anticancer therapy. Therefore, in this critical review, we summarize a range of nanomaterials which are currently being employed for anticancer therapies and discuss the fundamental role of their physicochemical properties in cancer management. We further elaborate on the topical progress made to date toward nanomaterial engineering for cancer therapy, including current strategies for drug targeting and release for efficient cancer administration. We also discuss issues of nanotoxicity, which is an often-neglected feature of nanotechnology. Finally, we attempt to summarize the current challenges in nanotherapeutics and provide an outlook on the future of this important field.

show abstract

pH sensitive liposomes delivering tariquidar and doxorubicin to overcome multidrug resistance of resistant ovarian cancer cells

Cited by 32 publications

References 28 publications

Formulation Strategies for Folate-Targeted Liposomes and Their Biomedical Applications

Formulation Strategies for Folate-Targeted Liposomes and Their Biomedical Applications

Fusion protein tTF-EG3287 induces occlusion of tumor vessels and impairs tumor growth in human colon cancer

Current trends and challenges in cancer management and therapy using designer nanomaterials

Contact Info

Product

Resources

About